Belite Bio surges after eye drug meets main goal in late-stage study

Belite Bio

01/12/2025 13:23

** Shares of drug developer Belite Bio BLTE.O rise 17.9% to $162 premarket

** Stock on track to open at record highs, if gains hold

** Co's genetic eye disease drug meets main goal in late-stage study

** The drug, tinlarebant, targets a progressive eye disease causing vision loss in childhood or adolescence

** The eye condition has no FDA-approved treatment currently

** Co says its drug slows the growth of damaging lesions in the retina

** BLTE plans to seek U.S. regulatory approval for the drug in the first half of 2026

** As of last close, BLTE stock has more than doubled YTD

 (Reporting by Utkarsh Tushar Hathi)

 ((utkarshtushar.hathi@thomsonreuters.com))